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Abstract
Background: Tinnitus is the perception of hearing a sound for which there is no external acoustic source. It is
often associated with sudden, temporary hearing loss and has a clear impact on a patient’s quality of life. Despite
numerous trials, there are no treatments that can be considered well established in terms of providing replicable
long-term tinnitus reduction. Complementary and alternative medical approaches have been employed to relieve
symptoms of tinnitus. Bojungikgitang and banhabaekchulchonmatang are among the most strongly preferred and
widely used herbal medicines for tinnitus in Korea, as they cause very few serious adverse effects.
We aim to establish basic clinical efficacy and safety data for bojungikgitang and banhabaekchulchonmatang,
which are approved as herbal medications by the Korea Food and Drug Administration in adult patients with
tinnitus.
Methods/Design: This study was a randomised, double-blind, placebo-controlled trial with three parallel arms
(bojungikgitang, banhabaekchulchonmatang, and a placebo). Participants included in the study met the following
criteria: typical conditions of intermittent or continuous tinnitus, for more than three months, with involuntary
perceptions of the concept of a sound in the absence of an external source. Participants received bojungikgitang,
banhabaekchulchonmatang, or a placebo-drug for eight weeks. The total duration of each arm was eleven weeks.
Each participant was examined for signs and symptoms of tinnitus before and after taking medication. Post-
treatment follow-up was performed two weeks after the final administration of medication.
Discussion: This trial provided evidence for the efficacy and safety of bojungikgitang and
banhabaekchulchonmatang in adult patients with tinnitus. The primary outcome measure was the Tinnitus
Handicap Inventory, an assessment used to identify difficulties that may be experienced due to tinnitus. The
secondary measures were included an Acoustic Examination and the Visual Analogue Scale. We employed the
Euro-Qol 5-Dimension and the Health Utilities Index Mark 3, a health-related quality of life questionnaire. Safety was
assessed by complete blood cell count, erythrocyte sedimentation rate, blood chemistry, urine analysis, PA chest
film, brain computed tomography, otologic examination, and vital signs.
Trial registration: Current Controlled Trials ISRCTN23691284
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Tinnitus is a common disorder,[1] with approximately
5-15% of the general population experiencing an unre-
mitting sensation of tinnitus [2]. Of patients who suffer
with the condition, 1 to 2% are seriously impaired.
Hearing loss, regardless of the cause, is the most impor-
tant risk factor for the development of tinnitus. The
condition can be severe enough to affect quality of life,
result in sleep disturbances, cause work impairment,
and lead to psychiatric distress in 1-3% of the general
population [3].
Despite considerable research, there is no generally
effective treatment for people who suffer from tinnitus
[4]. Attempts at pharmacological treatment of patients
who have tinnitus have proven to be disappointing. No
single drug has been shown to be effective in appropri-
ately controlled clinical trials [5,6]. There are also no
drugs approved by the United States Food and Drug
Administration (FDA) or the European Medicine
Agency for the treatment of tinnitus [7]. Recent patho-
physiological investigations have provided convincing
evidence that tinnitus is associated with abnormal activ-
ity in the central auditory system, with plastic transfor-
mations of the central auditory system, and with
abnormal links between the auditory and other see-
mingly non-related neural systems. This degree of com-
plexity may explain why no single drug has been shown
to be effective in the treatment of tinnitus [6].
In this context, various complementary and alternative
medicine (CAM) treatments have been administered for
tinnitus in clinical practice. Some studies have reported
the effectiveness of acupuncture or herbal medicine,
which is the most popular form of CAM therapy, for
the treatment of tinnitus when used alone or concomi-
tantly with usual care [8-11]. In the few number of trials
that have been conducted, the quality and the small
sample sizes of these studies make it difficult to reach
firm conclusions concerning these treatments. Well-
designed randomised controlled trials (RCTs) are
needed to examine the efficacy of treatments for
tinnitus.
The purpose of this study was to establish the basic
clinical efficacy and safety data for bojungikgitang and
banhabaekchulchonmatang, which are approved as her-
bal medications by the Korea Food and Drug Adminis-
tration (KFDA) in patients with tinnitus. Because of the
absence of a gold-standard for the treatment of tinnitus,
this trial will be conducted to detect the effectiveness of
these herbal medicines according to comparisons to a
placebo-controlled group.
The use of these herbal medicines for tinnitus was
based on the principles of Traditional Korean Medicine
(TKM). In this medical tradition, tinnitus usually results
from irregularities in bowel and visceral (zang-fu) func-
tioning. In TKM, bojungikgitang is administered to treat
the pattern of qi-deficiency and banhabaekchulchonma-
tang is used to treat the gallbladder deficiency associated
with tinnitus [8]. Both bojungikgitang and banhabaek-
chulchonmatang have disease codes related to tinnitus
in the Korean National Health Insurance Data
(KNHID), and they can be fully covered by Korean
National Health Insurance (KNHI).
We conducted a randomised, double-blind, three-arm,
placebo-controlled trial of bojungikgitang and banha-
baekchulchonmatang in adult patients with tinnitus.
Methods/Design
This study was a randomised, double-blind, three-arm,
placebo-controlled trial. Participants fulfilling eligibility
criteria were selected. Enrolled participants were ran-
domly allocated to three parallel groups: the bojungikgi-
tang, banhabaekchulchonmatang, and placebo arms.
Each participant was examined for signs and symptoms
of tinnitus before and after taking medication. A follow-
up to evaluate the maintenance of efficacy was per-
formed (Figure 1).
Recruitment
We recruited participants by advertisements in local
newspapers and on the websites of local medical centres
in Gyeonggi-province, Korea. Respondents were con-
tacted by clinical trial coordinators (CRC) to determine
eligibility via a telephone pre-screening. If an applicant
met the study criteria, he or she was invited to the clini-
cal research centre of the Wonkwang Univ. Sanbon
Oriental Medical Centre and was examined for eligibil-
ity. Oriental medicine doctors, ophthalmologists, and
gastroenterologists conducted the screening together to
improve the quality of eligibility assessment. Oriental
medicine doctors managed the whole process of screen-
ing. Ophthalmologists conducted the otologic examina-
tion and assessed the brain computed tomography (CT)
to identify and exclude conditions including otitis
media, acoustic tumours, head trauma, etc. Gastroenter-
ologists assessed the complete blood cell count (CBC),
erythrocyte sedimentation rate (ESR), blood chemistry,
PA chest film, and urine analysis to exclude patients
with serious liver and kidney disease.
Inclusion criteria
Eligible participants of both sexes who were 19 years
and older were enrolled according to the inclusion and
exclusion criteria. We defined the term tinnitus as a
subjective form of the disorder. Subjective tinnitus is the
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pants undergoing typical conditions of intermittent or
continuous tinnitus for three or more months. Partici-
pants were instructed to discontinue other treatments
for tinnitus during the run-in, treatment, and follow-up
periods. Written informed consent was obtained from
each participant.
Exclusion criteria
Participants were excluded if they suffered from serious
medical conditions, such as uncontrolled hypertension,
diabetes mellitus requiring insulin injection, past or cur-
rent malignancy, liver or kidney dysfunction, anaemia,
active pulmonary tuberculosis, or other infectious or
systemic diseases incompatible with treatment with her-
bal medicines.
Figure 1 Study Flow Chart.
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of other forms of tinnitus treatment; underlying disease
or history of otitis media, acoustic tumour, intracranial
lesion, inner ear malformation, head trauma, or the use
of ototoxic medications; pregnancy, lactation, or the lack
of a form of contraception; participation in another clin-
ical trial within one month of enrolment; auditory sur-
gery, a major surgery, or a blood transfusion within one
month of enrolment; hypersensitivity or allergic reac-
tions to herbal medicines that are related to this trial;
diseases that can affect the absorption of drugs or disor-
dered digestion after surgery related to such a disease;
history of a neuropsychiatric abnormality, such as
manic-depression, schizophrenia, alcoholism, drug
addiction, etc.; inability to understand written consent
or to engage in this study due to mental retardation or
other emotional or mental problems; or judgment by an
expert that the potential subject’s participation is
inappropriate.
Exclusion was primarily based on the information pro-
vided by the patients. Also, additional examinations,
such as CBC, ESR, blood chemistry, PA chest film, urine
analysis, Brain CT, otologic examination, and vital signs,
were performed before the trial to ensure that the
patients did not suffer from these diseases.
Over-the-counter (OTC) drugs were allowed for the
management of episodic colds, headaches, dyspepsia,
etc.; however, participants were gently advised to
reduce the doses, stop taking the supplements, or
refrain from adding other supplements to their regi-
men. Some OTC drugs, such as those containing
ginkgo or zinc, were not allowed, as there are concerns
that these drugs might have direct impacts on tinnitus.
These restrictions were based on the information pro-
vided by patients, and then the researchers evaluated
whether or not some of these components would
impact tinnitus.
We recorded the drugs taken by each participant at
every visit, and participants were asked to notify us of
any changes in their medication/supplement regimen.
Additional herbal prescriptions, acupuncture treatments,
or therapeutic interventions by other clinicians were not
allowed during the trial period. The complete eligibility
criteria are in Appendix 1.
Sample size and randomisation
We wished to estimate the sample size that would be suf-
ficient to detect significant differences in the Tinnitus
Handicap Inventory (THI) between the experimental and
control groups. Sample size was determined prospec-
tively, as described in a previous study [12]. The mean
and standard deviation of the expected difference scores
in THI were 6.550 and 6.778 between the experimental
and control group. The following formula was used to
estimate the sample size for a two-group trial:
n
za zb 

[
( / )
]. 2 2 

Calculations were performed using 80% power, a 5%
significance level, and a 25% dropout rate. The required
sample size was approximately 22 participants for each
group. It was necessary to increase the sample size by
30 per group for parametric estimation. We planned to
enrol 120 participants in each of the three groups,
allowing for a 25% withdrawal rate.
An expert on statistics who had direct contact with
the study participants conducted the randomisation of
participants. Participants were assigned random num-
bers via block randomisation using the SPSS statistical
package (Version 12.0; SPSS Inc., Chicago, IL). The
block size was concealed from other researchers, and
the randomisation table was not available for assessment
by anyone else involved in the study.
Opaque sealed envelopes containing serial numbers
were delivered to the clinical trial centre. Before the
random assignment, all participants were informed that
they would be allocated to one of three groups. Random
allocation was conducted at the second visit. Random
numbers with their corresponding participants were
determined in the order of the time of second visit. The
allocation results were not announced to the participants
until the last visit of the last randomised participant.
The success of blinding was assessed at each partici-
pant’s last visit. Researcher sw h ow e r eb l i n d e dt ot h e
allocation results performed the outcome assessment.
Treatment protocol
Participants received bojungikgitang, banhabaekchul-
chonmatang, or a placebo-drug for eight weeks. Oral
administration occurred according to the following
statements:
Patients in group 1 received bojungikgitang (see Addi-
tional file 1) and instructions on how to make the tea;
they consumed a packet of the medicine (12.52 g) with
tepid water three times a day at 30 minutes after meals.
Patients in group 2 received banhabaekchulchonma-
tang (see Additional file 2) and instructions on how to
make the tea; they consumed a packet of the medicine
(12.52 g) with tepid water three times a day at 30 min-
utes after meals.
Patients in group 3 received the placebo medicine (pow-
dered extract), used in the same way as in groups 1 and 2.
The defined daily doses (DDDs) of these herbal med-
icines should be determined based on the specifica-
tions and analytical procedures of drug products in
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reported so far.
Placebo medicine
Hanpoong Pharm and Foods Co., Ltd., produced the
placebo medicine according to Korea Good Manufactur-
ing Practice (KGMP) standards. They developed a
homogeneous powdered extract of yellow colour, which
was made by mixing 1.118 g of cornstarch, 1.118 g of
lactose, 6.80 g of Allura red, 1.05 g of Brilliant Blue, and
5.65 g of tartrazine. The colour, form, weight, odour,
and taste of the placebo were very similar to the treat-
ment medicines.
Permitted and prohibited concomitant treatments
Medical supplies for internal use, ointments, and other
goods not approved for medical treatment, but approved
by the Food and Drug Administration, could be used in
based diseases that have nothing to do with tinnitus
according to the customs. However, nutraceutical or
oriental medicines that have herbal ingredients and are
used in healthy people were prohibited.
Primary outcome measurement
THI was used as the primary outcome variable. The
purpose of this questionnaire was to identify difficulties
that may be experienced because of tinnitus. It measures
tinnitus-related cognitive, emotional, and social pro-
blems [13]. The THI consists of three scales: a Func-
tional subscale (eleven factors), an Emotional subscale
(nine factors), and a Catastrophic subscale (five factors).
It was measured at baseline (one week before treatment
initiation), at four weeks after the first medication
administration, at eight weeks after the first medication
administration, and at follow-up (two weeks after treat-
ment termination).
Secondary outcome measurement
Secondary outcome measures included the Acoustic
Examination (AE) and the Visual Analogue Scale (VAS).
Two VASs measuring the perceived loudness of tinnitus
and its impact on life were given. The VAS consists of
100-mm lines with endpoints denoted by the words
‘total absence’ and ‘maximum’. It was measured at base-
line (one week before treatment initiation), at four
weeks after the first medication administration, at eight
weeks after the first medication administration, and at
follow-up (two weeks after treatment termination). The
EuroQoL 5-Dimension (EQ-5D) and the Health Utilities
Index Mark 3 (HUI3) were measured at baseline, at
eight weeks after the first medication administration,
and at follow-up, as a measure of health outcomes. The
data collection schedule is detailed in Table 1.
Patient safety
All patients underwent routine testing that included the
following: complete blood cell count (CBC), erythrocyte
sedimentation rate (ESR), and blood chemistry, as well
as PA chest film and urine analysis before randomisa-
tion and immediately after completing the treatment.
Brain computed tomography (CT) and otologic exami-
nation were measured at baseline. Vital signs were
measured at every visit, except for the last visit. These
tests helped to identify and exclude patients with serious
liver and kidney disease as well as those with other
severe illnesses. Furthermore, the results of these tests
allowed for herbal medication-associated risks.
Statistical analysis
Analyses were performed for two populations: 1) an
intention-to-treat population consisting of all rando-
mised participants who have at least one measurable
Table 1 Data Collection Schedule
Period Screening Run-in phase Treatment period Follow- up
Visit 1st (D -7) 2nd (D 1) 3rd (D 29) 4th (D 57) 5th (D 71)
Informed Consent ○
Demographic Characteristics ○
Medical History ○
Safety Assessment ○○ ○ ○
Otologic Examination ○
Acoustic Examination ○○ ○ ○
Tinnitus Handicap Inventory ○○ ○ ○
Visual Analogue Scale ○○ ○ ○
EQ-5D ○○ ○
Health Utilities Index Mark 3 ○○ ○
Adverse Effects ○○○
Blinding Assessment ○
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replaced with the last observation values) and 2) a per-
protocol population including only participants without
major protocol deviations. All data were descriptively
analysed. All main analyses were based on the intention-
to-treat population. For primary and secondary outcome
measures, the mean differences from baseline values to
the end of treatment were compared using paired
T-test, ANOVA (analysis of variance), or MANOVA
(Multivariate Analysis of Variance). A trend test was
also performed using repeated measures analysis of var-
iance. We adjusted for possible confounders using the
criteria for statistical significance.
Statistical analyses were performed using the SPSS sta-
tistical package program (ver. 18.0), and the level of sig-
nificance was established at a = 0.05.
Data and safety monitoring
Monitoring was conducted for quality control. Investiga-
tors could also be convened to discuss practical issues
that might be encountered, such as dealing with serious
adverse events, revising the protocol, and addressing
certain important issues that might be raised by investi-
gators and participants.
We defined adverse events as unintended signs, symp-
toms, or disease occurring after treatment that were not
necessarily related to the intervention. The safety assess-
ment was based primarily on the frequency of adverse
events, which included all serious adverse events. Infor-
mation regarding adverse events was summarised by
presenting the number and percentage of participants
experiencing any adverse events.
Ethics
Written consent was obtained from each participant.
This study protocol was approved by the institutional
review board (IRB) of the Wonkwang University Orien-
tal Medical Centre.
Appendix 1. Eligibility Criteria
Inclusion criteria
￿ Age greater than 19 years of either sex
￿ Typical conditions of intermittent or continuous
tinnitus:
Duration of more than three months
Involuntary perception of the concept of a sound
without the presence of an external source
￿ Agree not to receive another treatment during the
clinical trial period
￿ Written and informed consent
Exclusion criteria
￿ Receiving other forms of tinnitus treatments
￿ Underlying disease or history of disease:
Otitis media
Acoustic tumour
Intracranial lesion
Inner ear malformation
Head trauma
Ototoxic drug medication, etc.
￿ Pregnant or lactating women
￿ Women not using contraception
￿ Participation in other clinical trials within the last
month
￿ Auditory surgery, a major surgery, or a blood
transfusion within the last month
￿ Drug hypersensitivities or allergies
￿ Diseases that can affect the absorption of drugs or
disordered digestion after surgery related to the
disease
￿ History of neuropsychiatric abnormality:
Manic-depression
Schizophrenia
Alcoholism
Drug addiction, etc.
￿ Inability to understand written consent or partici-
pate this study:
Mental retardation
Mental or emotional problems
￿ Judgment by an expert that the potential subject is
inappropriate for participation in the study
Additional file 1: Bojungikgitang. Components of bojungikgitang
Additional file 2: Banhabaekchulchonmatang. Components of
banhabaekchulchonmatang
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